TABLE 3.
MAb combinations used to analyze the composition and activation status of lymphocyte subsetsa
| Well no. | MAb combination |
|---|---|
| 1 (control) | |
| 2 | CD335, CD2, and TCR1 δ |
| 3 | CD25, CD4, and CD45R0 |
| 4 | CD26, CD25, and CD45R0 |
| 5 | CD71, CD25, and CD45R0 |
| 6 | ACT1, CD25, and CD45R0 |
| 7 | ACT16, CD25, and CD45R0 |
| 8 | CD25, CD8, and CD45R0 |
| 9 | CD26, CD8, and CD45R0 |
| 10 | CD71, CD8, and CD45R0 |
| 11 | ACT1, CD8, and CD45R0 |
| 12 | ACT16, CD8, and CD45R0 |
a
Each well contains three antibodies of differing isotypes. With the use of isotype-specific second antibodies conjugated to different fluorochromes, cell subsets labeled with the antibodies appear in separate cytometer channels, as noted in the figures. The control well contains secondary antibodies but no primary antibodies. The control well is used to show that the secondary antibodies do not label cells nonspecifically.